Online citations, reference lists, and bibliographies.
← Back to Search

Formulation And Nebulization Of Fluticasone Propionate-loaded Lipid Nanocarriers.

A. Umerska, C. R. Mouzouvi, A. Bigot, P. Saulnier
Published 2015 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Inhaled fluticasone propionate (FP) is often prescribed as a first-line therapy for the effective management of pulmonary diseases such as asthma. As nanocarriers offer many advantages over other drug delivery systems, this study investigated the suitability of lipid nanocapsules (LNCs) as a carrier for fluticasone propionate, examining the drug-related factors that should be considered in the formulation design and the behaviour of LNCs with different compositions and properties suspended within aerosol droplets under the relatively hostile conditions of nebulization. By adjusting the formulation conditions, particularly the nanocarrier composition, FP was efficiently encapsulated within the LNCs with a yield of up to 97%, and a concentration comparable to commercially available preparations was achieved. Moreover, testing the solubility of the drug in oil and water and determining the oil/water partition coefficient proved to be useful when assessing the encapsulation of the FP in the LNC formulation. Nebulization did not cause the FP to leak from the formulation, and no phase separation was observed after nebulization. LNCs with a diameter of 100 nm containing a smaller amount of surfactant and a larger amount of oil provided a better FP-loading capacity and better stability during nebulization than 30 or 60 nm LNCs.
This paper references
10.1016/j.ijpharm.2014.10.023
Intermolecular interactions between salmon calcitonin, hyaluronate, and chitosan and their impact on the process of formation and properties of peptide-loaded nanoparticles.
A. Umerska (2014)
10.1002/jps.21380
Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies.
J. Z. Yang (2008)
10.1016/j.ejpb.2013.08.013
Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art.
S. Weber (2014)
10.1016/S0168-3659(02)00370-X
Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features.
L. A. Dailey (2003)
10.1016/J.JCONREL.2006.02.014
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition.
A. Lamprecht (2006)
NEBULIZATION OF LIPOSOMES: I-EFFECT OF LIPID COMPOSITION
R. Niven (1990)
10.1016/j.ijpharm.2009.10.012
Surface active drugs significantly alter the drug output rate from medical nebulizers.
A. Arzhavitina (2010)
10.1016/j.ejpb.2015.04.006
Chondroitin-based nanoplexes as peptide delivery systems--Investigations into the self-assembly process, solid-state and extended release characteristics.
A. Umerska (2015)
10.1016/J.TIBTECH.2007.09.005
Nanoparticles for drug delivery to the lungs.
Jean Sung (2007)
10.1023/A:1016121319668
A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers
B. Heurtault (2004)
10.1016/J.COLSURFB.2005.03.009
Reorganization of lipid nanocapsules at air-water interface. I. Kinetics of surface film formation.
I. Minkov (2005)
10.1111/j.2042-7158.2010.01024.x
Lipid nanoparticles for the delivery of poorly water‐soluble drugs
H. Bunjes (2010)
10.1016/S1359-0294(02)00008-0
Particles as surfactants—similarities and differences
B. Binks (2002)
10.1073/pnas.182233999
Trojan particles: Large porous carriers of nanoparticles for drug delivery
N. Tsapis (2002)
10.1016/S0927-7765(03)00096-1
Interfacial stability of lipid nanocapsules
B. Heurtault (2003)
10.1016/S0378-5173(98)00055-6
Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin
W. Finlay (1998)
10.1007/s11671-010-9597-y
Evaluating the Suitability of Using Rat Models for Preclinical Efficacy and Side Effects with Inhaled Corticosteroids Nanosuspension Formulations
Po-Chang Chiang (2010)
10.1002/jps.21714
Pharmacokinetic and pharmacodynamic evaluation of the suitability of using fluticasone and an acute rat lung inflammation model to differentiate lung versus systemic efficacy.
Po-Chang Chiang (2009)
10.1016/S0168-3659(02)00258-4
New lipid nanocapsules exhibit sustained release properties for amiodarone.
Alf Lamprecht (2002)
10.1002/med.20140
Nanoparticle formulations in pulmonary drug delivery
Mark M. Bailey (2009)
10.1023/A:1015896121377
Nebulization of Liposomes. II. The Effects of Size and Modeling of Solute Release Profiles
R. Niven (2004)
10.1016/j.colsurfb.2009.09.033
Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC).
S. Doktorovová (2010)
10.1016/0378-5173(96)04449-3
Nebulisation of monodisperse latex sphere suspensions in air-jet and ultrasonic nebulisers
Orla N.M. Mc Callion (1996)
10.1053/RMED.2001.1143
The importance of the device in asthma therapy.
L. Borgström (2001)
10.1016/S0168-3659(02)00264-X
A facile method of delivery of liposomes by nebulization.
T. Desai (2002)
10.1016/j.ijpharm.2012.06.019
Evaluation of surface deformability of lipid nanocapsules by drop tensiometer technique, and its experimental assessment by dialysis and tangential flow filtration.
Samuli Hirsjärvi (2012)
10.1016/S0091-6749(98)70156-3
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids.
H. Derendorf (1998)
10.1016/j.addr.2007.11.006
Targeted delivery of nanoparticles for the treatment of lung diseases.
S. Azarmi (2008)
10.1016/S0939-6411(99)00049-1
An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization.
K. Ostrander (1999)
10.1016/j.ijpharm.2009.04.026
Lipid nanocapsules: a new platform for nanomedicine.
N. Huynh (2009)
10.1007/PL00022055
Iloprost-Containing Liposomes for Aerosol Application in Pulmonary Arterial Hypertension: Formulation Aspects and Stability
E. Kleemann (2006)
10.1016/j.ijpharm.2008.01.046
Inhalable liposomal formulation for vasoactive intestinal peptide.
Franz Hajos (2008)
10.1016/j.addr.2014.05.001
Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.
D. Cipolla (2014)
10.1016/j.ejpb.2010.02.003
Influence of the introduction of a solubility enhancer on the formulation of lipidic nanoparticles with improved drug loading rates.
A. Malzert‐Fréon (2010)
10.1016/j.ijpharm.2008.09.017
Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model.
M. Beck-Broichsitter (2009)
10.1023/A:1015924124180
Nebulization of Liposomes. I. Effects of Lipid Composition
R. Niven (2004)
10.1016/J.RMED.2005.11.020
Systemic side effects of inhaled corticosteroids in patients with asthma.
R. Dahl (2006)
10.1166/JBN.2014.1878
Self-assembled hyaluronate/protamine polyelectrolyte nanoplexes: synthesis, stability, biocompatibility and potential use as peptide carriers.
A. Umerska (2014)
10.1016/J.IJPHARM.2004.03.018
Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment.
Alf Lamprecht (2004)
10.1016/J.ADDR.2006.07.012
In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
M. Sakagami (2006)
Fluticasone Propionate Liposomes for Pulmonary Delivery
N. M. Nirale (2009)
10.1016/S0927-7757(03)00249-8
Viscoelastic properties of concentrated dispersions in water of soy lecithin
M. Manconi (2003)
10.1016/j.ejpb.2009.06.013
Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.
J. Hureaux (2009)
10.1166/JCSB.2012.1010
Encapsulation and Release Behavior from Lipid Nanoparticles: Model Study with Nile Red Fluorophore
Thomas Delmas (2012)



This paper is referenced by
10.1007/s11064-020-03122-y
Lipid Nanoparticles Vectorized with NFL-TBS.40-63 Peptide Target Oligodendrocytes and Promote Neurotrophin-3 Effects After Demyelination In Vitro.
C. Fressinaud (2020)
10.1371/journal.pone.0179211
Surface active properties of lipid nanocapsules
C. R. Mouzouvi (2017)
10.1016/j.cbi.2018.12.009
Increasing complexity and interactions of oxidative stress in chronic respiratory diseases: An emerging need for novel drug delivery systems.
K. Dua (2019)
10.1016/j.jddst.2020.101605
Novel biocompatible essential oil-based lipid nanocapsules with antifungal properties
Aya M. Hussein (2020)
10.2147/IJN.S146740
Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats
J. Hureaux (2017)
10.1016/j.powtec.2020.02.028
Carbohydrate-based Trojan microparticles as carriers for pulmonary delivery of lipid nanocapsules using dry powder inhalation
Anita Umerska (2020)
10.1016/j.ijpharm.2016.04.028
Understanding the adsorption of salmon calcitonin, antimicrobial peptide AP114 and polymyxin B onto lipid nanocapsules.
A. Umerska (2016)
10.3390/nano7080222
Polyaspartamide-Based Nanoparticles Loaded with Fluticasone Propionate and the In Vitro Evaluation towards Cigarette Smoke Effects
E. Craparo (2017)
10.2147/IJN.S139625
Synergistic interactions between antimicrobial peptides derived from plectasin and lipid nanocapsules containing monolaurin as a cosurfactant against Staphylococcus aureus
A. Umerska (2017)
10.1371/journal.pone.0189950
Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity
H. Nehme (2018)
10.1016/j.ejpb.2016.09.001
Antibacterial action of lipid nanocapsules containing fatty acids or monoglycerides as co-surfactants.
A. Umerska (2016)
10.1016/j.ijpharm.2015.11.042
Synergistic interactions between doxycycline and terpenic components of essential oils encapsulated within lipid nanocapsules against gram negative bacteria.
C. Valcourt (2016)
10.1002/btm2.10118
Engineering, on‐demand manufacturing, and scaling‐up of polymeric nanocapsules
J. Crecente-Campo (2019)
Semantic Scholar Logo Some data provided by SemanticScholar